2019

Kardium® announces successful results from the GLOBAL-AF study (Financial Post)

October 8, 2019

Global-AF study demonstrated a 76% percent freedom from atrial fibrillation at 12 months after a single treatment with the Globe System.

Read More

Kardium® announces successful results from the GLOBAL-AF study

October 8, 2019

October 8, 2019 9:00 AM Pacific Standard Time VANCOUVER, British Columbia — Kardium Inc. today announced that the Globe® Mapping and Ablation System has successfully demonstrated safety and efficacy in the GLOBAL-AF study.  The results of the study were published in the Journal of Cardiovascular Electrophysiology. The study demonstrated a 76% percent freedom from atrial […]

Read More

Kardium Announces New Financing to Commercialize the Globe System for the Treatment of Atrial Fibrillation (Cardiac Vascular News)

February 7, 2019

Financing was led by funds and accounts advised by T. Rowe Price Associates, Inc., and included participation from other new and existing Kardium shareholders.

Read More

Kardium® announces new financing to commercialize the Globe® System for the treatment of atrial fibrillation

January 24, 2019

T. Rowe Price leads new round of financing together with new and existing investors January 24 2019 10:00 AM Pacific Standard Time VANCOUVER, B.C. – Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, announced today that it has raised an undisclosed amount in a new financing round. […]

Read More